| Nov 12, 2009
On November 2, Biogen Idec updated the prescribing label for its blockbuster multiple sclerosis drug Tysabri(natalizumab) after consultation with the FDA. Aside from acknowledging that the risk of developing progressive multifocal leukoencephalopathy (PML), an often fatal brain infection, increases with longer duration of treatment, no other revisions concerning the risk of PML were required. The fact that this biologic remains a cornerstone treatment for adult patients with relapsing forms of MS — only the second drug to ever return to U.S. pharmacy shelves after having been withdrawn — speaks volumes to the growing influence of the Web.
The Internet has radically changed pharmaceutical marketing and sales. No longer do drug companies need legions of attractive and personable salespeople to “detail” physicians on the efficacy and patient benefits of their choice drugs.
0 comments:
Post a Comment